GlassScriptPhysician profile
Katelyn Hammrich
NPI 1003463902
$3,725.70
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $1,004 · 2023: $1,517 · 2024: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.51 | 2021-2024 | |
| Glaxosmithkline, LLC. | $542.93 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $415.75 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $223.02 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $183.51 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $167.02 | 2021-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $166.16 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Nestle Healthcare Nutrition INC. | $111.76 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.50 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $100.43 | 2021-2023 | |
| Abbott Laboratories | $98.82 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $95.06 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.90 | 2021-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $86.73 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $77.82 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $63.15 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $60.28 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $53.56 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $49.82 | 2021-2023 | Gardasil 9, Vaxneuvance |
| Sunovion Pharmaceuticals INC. | $48.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.07 | 2022-2024 | Xifaxan, Trulance |
| Almatica Pharma LLC | $32.97 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Sanofi Pasteur INC. | $24.21 | 2021 | |
| Insulet Corporation | $23.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.24 | 2022 | |
| Edwards Lifesciences Corporation | $22.60 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Otsuka America Pharmaceutical, INC. | $19.76 | 2024 | Rexulti |
| Organon LLC | $18.74 | 2023 | Nexplanon |
| Janssen Pharmaceuticals, INC | $17.40 | 2022 | |
| Amarin Pharma, INC. | $15.85 | 2022 | |
| Grifols USA, LLC | $14.59 | 2021 | |
| Aimmune Therapeutics, INC. | $13.53 | 2024 | |
| Dexcom, INC. | $13.53 | 2021 | |
| Qiagen, LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Hammrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.